CHI3L1 and myeloid sarcoma: In this context, the aim of our study is to measure CSF level of CHI3L1 in MS patients and correlate its level with different aspects of disability including EDSS, cognition, and radiological aspects and if it could be used as an objective biomarker for disease progression.